Xenon Pharmaceuticals (XENE) Payables (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Payables data on file, last reported at $5.7 million in Q1 2026.

• On a quarterly basis, Payables fell 16.48% year-over-year to $5.7 million in Q1 2026; TTM through Mar 2026 was $5.7 million, a 16.48% decrease from a year earlier, with the FY2025 full-year figure at $3.9 million, down 88.65% from the prior year.
• Payables for Q1 2026 stood at $5.7 million, up from $3.9 million in the prior quarter.
• Over the last five years, Payables for XENE reached as high as $36.8 million in Q3 2025 and fell as low as $3.9 million in Q4 2025.
• Historically, Payables has averaged $18.7 million across 5 years, with a median of $15.5 million in 2022.
• Across the five-year window, Payables surged 403.63% in 2022 and slumped 88.65% in 2025, its largest moves.
• Year by year, Payables stood at $8.5 million in 2022, then surged by 205.9% to $26.0 million in 2023, then soared by 31.75% to $34.2 million in 2024, then slumped by 88.65% to $3.9 million in 2025, then jumped by 47.95% to $5.7 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $5.7 million in Q1 2026, $3.9 million in Q4 2025, and $36.8 million in Q3 2025.